Tango's PRMT5 inhibitor paired with Revolution Medicines' pan RAS inhibitor shrank tumors in patients with few options left, putting a biology driven combination strategy in front of biotech dealmakers.
A pairing of two experimental drugs just gave synthetic lethality its most concrete test in one of oncology's hardest cancers. Tango Therapeutics' PRMT5 inhibitor combined with Revolution Medicines' pan-RAS inhibitor shrank tumors in advanced pancreatic cancer patients who had run out of standard options, according to Adam Feuerstein's Adam's Biotech Scorecard column in STAT, published June 11, 2026.
Pancreatic cancer has long been one of the deadliest common tumors, and KRAS-mutated disease, which dominates the patient population, has shrugged off most targeted attempts over the past decade. A combination that works through two separate biological weaknesses at once is a different kind of bet, and an early signal of tumor shrinkage is the kind of result that tends to bring dealmakers into the room.
The mechanism is what the field calls synthetic lethality. Two genes are synthetic lethal when disabling either one alone leaves a cell alive, but disabling both kills it. A tumor that has already lost the function of one gene is uniquely vulnerable to a drug that disables its partner gene, and that asymmetry is what makes synthetic lethality rational as a combination strategy rather than just convenient. Tango's PRMT5 inhibitor targets a gene involved in how cells process RNA, and Revolution Medicines' pan-RAS inhibitor jams the molecular switch KRAS uses to drive growth. Each is supposed to weaken the tumor in a way that makes the other work better, which is the synthetic-lethality promise applied to combinations rather than monotherapy.
Feuerstein's column is explicit that the M&A scenario layered on top is speculation, not reporting. He names Revolution Medicines as a potential acquirer of Tango Therapeutics and flags Bristol Myers Squibb as another possible buyer, and he is candid that no acquisition has been announced or rumored. The deal framing is one read of the clinical signal rather than a forecast. Feuerstein, who also co-hosts STAT's biotech podcast The Readout Loud, treats the deal question as a way of framing the science, and the science is the part with real evidence behind it.
That evidence is early. Combination data in pancreatic cancer is notoriously noisy, and a small set of responders does not yet show that the effect holds in a larger randomized test. Several earlier synthetic-lethality pairings have produced similar early buzz that did not survive a pivotal trial. The biology is rational, the data is promising, and the history of the field is littered with combinations that read well at fifteen patients and faded at two hundred.
What to watch next is concrete. Future clinical updates from the program, which could come through a medical meeting, a press release, or an investor presentation, will reveal whether tumor shrinkage rates hold and whether responders stay on therapy long enough to suggest a real survival benefit. The next earnings calls from both companies will show whether they are funding the program alone, looking for a partner, or sitting on a suitor. And any disclosure of licensing or partnership talks will, in a field where combinations need both halves to be in play, do more to move the deal question than any analyst note.
The pancreatic cancer community has been waiting a long time for a targeted therapy that works. A combination built on synthetic-lethality logic is a credible answer to that wait, but it is also a hypothesis with a long way to go.